SG Americas Securities LLC Boosts Stake in ACADIA Pharmaceuticals Inc. $ACAD

SG Americas Securities LLC grew its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 84.0% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 77,208 shares of the biopharmaceutical company’s stock after purchasing an additional 35,243 shares during the period. SG Americas Securities LLC’s holdings in ACADIA Pharmaceuticals were worth $1,719,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Farther Finance Advisors LLC grew its holdings in ACADIA Pharmaceuticals by 67.5% in the fourth quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 386 shares during the last quarter. Cetera Investment Advisers grew its stake in ACADIA Pharmaceuticals by 2.7% in the 4th quarter. Cetera Investment Advisers now owns 16,355 shares of the biopharmaceutical company’s stock valued at $437,000 after acquiring an additional 436 shares during the last quarter. J.W. Cole Advisors Inc. raised its position in ACADIA Pharmaceuticals by 2.5% during the fourth quarter. J.W. Cole Advisors Inc. now owns 20,632 shares of the biopharmaceutical company’s stock worth $551,000 after acquiring an additional 501 shares during the last quarter. Pallas Capital Advisors LLC raised its position in shares of ACADIA Pharmaceuticals by 4.0% during the 4th quarter. Pallas Capital Advisors LLC now owns 13,192 shares of the biopharmaceutical company’s stock worth $352,000 after purchasing an additional 512 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its position in shares of ACADIA Pharmaceuticals by 11.2% during the 3rd quarter. PNC Financial Services Group Inc. now owns 5,323 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 534 shares during the last quarter. 96.71% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at ACADIA Pharmaceuticals

In other news, EVP Mark C. Schneyer sold 3,506 shares of the business’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $21.79, for a total transaction of $76,395.74. Following the completion of the sale, the executive vice president directly owned 66,145 shares of the company’s stock, valued at $1,441,299.55. The trade was a 5.03% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider James Kihara sold 5,401 shares of the company’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $21.18, for a total value of $114,393.18. Following the sale, the insider owned 24,509 shares of the company’s stock, valued at approximately $519,100.62. The trade was a 18.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 13,978 shares of company stock valued at $302,819 in the last ninety days. 26.20% of the stock is currently owned by company insiders.

ACADIA Pharmaceuticals Trading Up 3.1%

Shares of NASDAQ:ACAD opened at $25.97 on Friday. The stock’s 50-day moving average price is $22.11 and its two-hundred day moving average price is $23.40. ACADIA Pharmaceuticals Inc. has a 12-month low of $19.69 and a 12-month high of $28.35. The firm has a market cap of $4.45 billion, a price-to-earnings ratio of 11.80, a PEG ratio of 18.15 and a beta of 0.80.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). The company had revenue of $268.10 million for the quarter, compared to analyst estimates of $280.25 million. ACADIA Pharmaceuticals had a net margin of 34.30% and a return on equity of 9.61%. The company’s revenue was up 9.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.11 EPS. As a group, research analysts forecast that ACADIA Pharmaceuticals Inc. will post 0.37 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently issued reports on ACAD. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $37.00 target price on shares of ACADIA Pharmaceuticals in a research note on Monday. Citigroup lifted their price target on shares of ACADIA Pharmaceuticals from $32.00 to $35.00 and gave the stock a “buy” rating in a report on Monday. Canaccord Genuity Group boosted their price objective on shares of ACADIA Pharmaceuticals from $32.00 to $36.00 and gave the company a “buy” rating in a research report on Monday. Weiss Ratings downgraded shares of ACADIA Pharmaceuticals from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 1st. Finally, Bank of America raised their target price on shares of ACADIA Pharmaceuticals from $29.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday. Twelve equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.59.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.